{
    "root": "7dd364be-9dc4-4702-837c-97441a679094",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "EXEMESTANE",
    "value": "20250520",
    "ingredients": [
        {
            "name": "EXEMESTANE",
            "code": "NY22HMQ4BX"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "MAGNESIUM CARBONATE",
            "code": "0E53J927NA"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        }
    ],
    "indications": "exemestane aromatase inhibitor indicated : • adjuvant treatment postmenopausal women estrogen-receptor positive early breast cancer received two three years tamoxifen switched exemestane completion total five consecutive years adjuvant hormonal therapy ( 14.1 ) . • treatment advanced breast cancer postmenopausal women whose disease progressed following tamoxifen therapy ( 14.2 ) .",
    "contraindications": "recommended dose : one 25 mg tablet daily meal ( 2.1 ) .",
    "warningsAndPrecautions": "exemestane tablets round , biconvex , off-white slightly greyish sugar-coated tablets , 6 mm diameter , printed numbers 2858 one side black ink . tablet contains 25 mg exemestane . exemestane packaged hdpe bottles child-resistant screw cap , supplied packs 30 tablets . 30-tablet hdpe bottle ndc 59762-2858-1",
    "adverseReactions": "exemestane contraindicated patients known hypersensitivity excipients .",
    "indications_original": "EXEMESTANE is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to EXEMESTANE for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ).",
    "contraindications_original": "Recommended Dose: One 25 mg tablet once daily after a meal ( 2.1 ).",
    "warningsAndPrecautions_original": "EXEMESTANE tablets are round, biconvex, off-white to slightly greyish sugar-coated tablets, about 6 mm diameter, printed with numbers 2858 on one side in black ink. Each tablet contains 25 mg of exemestane. EXEMESTANE is packaged in HDPE bottles with a child-resistant screw cap, supplied in packs of 30 tablets.\n                       30-tablet HDPE bottle            NDC 59762-2858-1",
    "adverseReactions_original": "EXEMESTANE is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients."
}